RESPONSE OF KEL OID FIBROBLASTS TO VITAMIN D3 AND QUERCETIN TREATMENT-IN VITRO STUDY TRAITEMENT DES FIBROBLASTES CHELOIDIENS PAR LA VITAMINE D ET LA QUERCETINE: ETUDE IN VITRO

Both hypertrophic and keloid scars are caused by abnormal wound healing, the key feature being excess collagen secretion by fibroblasts. Both keloid and hypertrophic scars are considered dermal fibro proliferative diseases that differ both clinically and histopathologically. Keloids are benign, fibroproliferative lesions that result in excessive fibrosis. They are composed of mainly type III (early) or type I (late) collagen. Some of the symptoms include pruritus, tenderness, and pain. Often, they are very difficult to treat and recurrence is very common. In contrast to hypertrophic scars, keloids extend beyond the original confines of the wound. Because of the central role played by collagen in the wound healing process, control of collagen synthesis by fibroblasts has been of paramount importance in abrogating abnormal wound healing to prevent the development of hypertrophic scarring and keloids. Multiple treatments have been advocated in the past with varied success. Treatment of keloid scars currently includes surgery, intralesional corticosteroids, pressure garments, tamoxifen, and interferon therapy, with different treatment regimens resulting in varying degrees of recurrence. Most of the literature on keloid treatment suggests that a high rate of recurrence (50%-70%) prevails during their management. Recent in vitro studies on novel therapeutic approaches for treating keloids suggest that Vitamin D3 and quercetin RESPONSE OF KEL OID FIBROBLASTS TO VITAMIN D3 AND QUERCETIN TREATMENT IN VITRO STUDY